讲者:Nicholas C.Turner,MD,PhD|The Institue of Cancer Research,Royal Cancer Hospital 摘要号:503 Effects of ovarian ablation or suppression on breast cancer recurrence and survival:Patient-level meta-analysis of 14,993 pre-menopausal women in 25 randomized trials. 卵巢切除或卵巢抑制对乳腺癌复发和生存...
标题:Impact of body mass index and its change on survival outcomes in patients with early breast cancer: a pooled analysis of individual-level data from BCIRG-001 and BCIRG-005 trials 报告人:陈海珠(中国,广州) 时间:16:40 - 16:45 04 摘要号:240MO 标题:Prognostic and predictive impact of e...
Track 17: Breast Cancer Clinical Trials Clinical trials are critical to advancing breast cancer treatment, testing new drugs, therapies, and combinations. By participating in clinical trials, patients help improve treatment options for future generations. These trials also focus on risk reduction, diagno...
Pathological complete response (pCR) after neoadjuvant systemic treatment (NST) is an important prognostic factor in HER2-positive breast cancer. The majority of HER2-positive breast cancers are amplified at the HER2 gene locus, several genes are co-amplified with HER2, and a subset of them are ...
Breast Cancer Research is the highest ranking breast cancer-specific title in the top quartile of oncology journals worldwide. Primarily publishing original ...
BREAST cancerTRIPLE-negative breast cancerEPIDERMAL growth factor receptorsCLINICAL trialsBreast cancer has become the most common type of cancer in the world, harming the majority of women's physical and mental health and challenging clinical prevention and treatm...
Breast Cancer: Metastatic - Triple Negative Cancer Health Disparities Cancer Survivorship and Quality of Life Clinical Biomarkers, Translational Research, and Precision Medicine Drug Discovery, Design, and Delivery Experimental Therapeutics and Early Phase Trials ...
The tumour immune microenvironment is shaped by the crosstalk between cancer cells, immune cells, fibroblasts, endothelial cells and other stromal components. Although the immune tumour microenvironment (TME) serves as a source of therapeutic targets, it
日期:2023年10月22日 时间:08:30～10:00 地点:Bilbao Auditorium-NCC 379MO-Datopotamab deruxtecan(Dato-DXd)+durvalumab(D)as first-line(1L)treatment for unresectable locally advanced/metastatic triple-negative breast cancer(a/mTNBC):updated results from BEGONIA,a phase 1b/2 study ...
The long-sought discovery of HER2 as an actionable and highly sensitive therapeutic target was a major breakthrough for the treatment of highly aggressive HER2-positive breast cancer, leading to approval of the first HER2-targeted drug — the monoclonal